Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company focused on innovative health and wellness solutions, announces the execution of a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group, a pioneering health innovation company specializing in advanced intranasal drug delivery technologies. The LOI, fully executed by both parties, outlines the proposed acquisition of 100% of Bio-Legacy Evaluative Group’s equity interests, assets, intellectual property, and operations in exchange for $1.5 million worth of Branded Legacy’s Preferred D stock.
Read the full article: Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery //
Source: https://www.globenewswire.com/news-release/2025/07/29/3123234/0/en/Branded-Legacy-Inc-Signs-Letter-of-Intent-to-Acquire-Bio-Legacy-Evaluative-Group-Advancing-Innovations-in-Intranasal-Drug-Delivery.html